Le LAB'O, Orleans Technopole, 1 avenue du Champs de Mars, 45074, Orleans, France.
Biomed Eng Online. 2020 Dec 3;19(1):91. doi: 10.1186/s12938-020-00835-7.
Most critically ill Covid-19 patients succumb to multiple organ failure and/or sudden cardiac arrest (SCA) as a result of comorbid endothelial dysfunction disorders which had probably aggravated by conventional mechanical assist devices. Even worse, mechanical ventilators prevent the respiratory pump from performing its crucial function as a potential generator of endothelial shear stress (ESS) which controls microcirculation and hemodynamics since birth. The purpose of this work is to bring our experience with ESS enhancement and pulmonary vascular resistance (PVR) management as a potential therapeutic solution in acute respiratory distress syndrome (ARDS). We propose a non-invasive device composed of thoracic and infradiaphragmatic compartments that will be pulsated in an alternating frequency (20/40 bpm) with low-pressure pneumatic generator (0.1-0.5 bar). Oxygen supply, nasogastric with, or without endotracheal tubes are considered.
大多数危重症 COVID-19 患者因合并的内皮功能障碍疾病而导致多器官衰竭和/或心搏骤停 (SCA)，这些疾病可能因传统的机械辅助设备而加重。更糟糕的是，机械呼吸机阻止呼吸泵发挥其作为内皮剪切应力 (ESS) 的潜在发生器的关键功能，ESS 控制着微循环和血流动力学从出生开始。这项工作的目的是将我们在增强 ESS 和管理肺血管阻力 (PVR) 方面的经验作为急性呼吸窘迫综合征 (ARDS) 的潜在治疗方法。我们提出了一种由胸和膈肌下腔组成的非侵入性设备，该设备将以交替频率 (20/40 bpm) 进行脉动，使用低压气动发生器 (0.1-0.5 巴)。考虑使用氧气供应、鼻胃管和/或气管内管。
